New investigational drugs for the management of acute heart failure syndromes

Current Medicinal Chemistry

Volumn 17, Issue 4, 2010, Pages 363-390

  Tamargo, J ^a   Amoros I ^a   Barana, A ^a   Caballero, R ^a   Delpon E ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

Acute heart failure syndromes; Adenosine antagonists; Cardiac myosin activators; Inotropes; Ixtaroxime; Levosimendan; Metabolic modulators; Natriuretic peptides; Relaxin; Vasodilators; Vasopressin antagonists

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 3 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)BICYCLO[2.2.2]OCTAN 1 YL]PROPIONIC ACID; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; 6 OXO 3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL) 1(6H) PYRIDAZINEBUTYRIC ACID; AC 2592; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; ALISKIREN; CALCIUM SENSITIZER; CARDIAC MYOSIN; CFM 1571; CK 0689705; CK 112253; CK 1122534; CK 1213296; CK 1827452; CL 385004; CONIVAPTAN; CY 1; DIURETIC AGENT; ED 57033; ENDOTHELIN RECEPTOR ANTAGONIST; ETOMOXIR; FAD 286; GUANYLATE CYCLASE ACTIVATOR; HMR 1766; INOTROPIC AGENT; ISTAROXIME; IVABRADINE; JTV 605; LCI 699; LEVOSIMENDAN; LIXIVAPTAN; MILRINONE; MK 7418; MOZAVAPTAN; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NATRIURETIC FACTOR; NAXIFYLLINE; NESIRITIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OXFENICINE; PERHEXILINE; PST 2744; RANOLAZINE; RELAXIN; RELCOVAPTAN; RENIN INHIBITOR; ROLOFYLLINE; RWJ 351647; RWJ 676070; SATAVAPTAN; SPP 2475; TEZOSENTAN; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URODILATIN; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST; VASOPRESSIN RECEPTOR ANTAGONIST; VP 343;

ACUTE HEART FAILURE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; NONHUMAN; OUTCOMES RESEARCH; REVIEW;

ACUTE DISEASE; ANIMALS; CARDIOTONIC AGENTS; DIURETICS; DRUG DISCOVERY; HEART FAILURE; HUMANS; SYNDROME; VASODILATOR AGENTS;

EID: 77950686341     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790192721     Document Type: Review

References (195)

1. Nieminen, M.S.; Böhm, M.; Cowie, M.R.; Drexler, H.; Filippatos, G.S.; Jondeau, G.; Hasin, Y. Lopez-Sendon, J.; Mebazaa, A.; Metra, M.; Rhodes, A.; Swedberg, K.; Priori, S.G.; Garcia, M.A.; Blanc, J.J.; Budaj, A.; Cowie, M.R.; Dean, V.; Deckers, J.; Burgos, E.F.; Lekakis, J.; Lindahl, B.; Mazzotta, G.; Morais, J.; Oto, A.; Smiseth, O.A.; Garcia, M.A.; Dickstein, K.; Albuquerque, A.; Conthe, P.; Crespo-Leiro, M.; Ferrari, R.; Follath, F.; Gavazzi, A.; Janssens, U.; Komajda, M.; Morais, J.; Moreno, R.; Singer, M.; Singh, S.; Tendera, M.; Thygesen, K. ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart J., 2005, 26, 384-416. (Pubitemid 40283098)
2. Gheorghiade, M.; Zannad, F.; Sopko, G.; Klein, L.; Piña, I.L.; Konstam, M.A.; Massie, B.M.; Roland, E.; Targum, S.; Collins, S.P.; Filippatos, G.; Tavazzi, L. International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation, 2005, 112, 3958-3968.
3. Heart Failure Society Of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J. Card. Fail., 2006, 12, 10-38.
4. Dickstein, K.; Cohen-Solal, A.; Filippatos, G.; McMurray, J.J.; Ponikowski, P.; Poole-Wilson, P.A.; Strömberg, A.; van Veldhuisen, D.J.; Atar, D.; Hoes, A.W.; Keren, A.; Mebazaa, A.; Nieminen, M.; Priori, S.G.; Swedberg, K.; ESC Comité for Practice Guidelines, Vahanian, A; Camm, J.; De Caterina, R.; Dean, V.; Dickstein, K.; Filippatos, G.; Funck-Brentano, C.; Hellemans, I.; Kristensen, S.D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, M.; Widimsky, P.; Zamorano, J.L. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. Heart J., 2008, 29, 2388-2444.
5. Allay, F.; Zannad, F.; Filippatos, G. Epidemiology of acute heart failure syndromes. Heart Fail. Rev., 2007, 12, 91-95. (Pubitemid 46916953)
6. Gheorghiade, M. Acute heart failure syndromes. J. Am. Coll. Cardiol., 2009, 53,557-573.
7. Fang, J.; Mensah, G.A.; Croft, J.B.; Keenan, N.L. Heart failurerelated hospitalization in the U.S., 1979 to 2004. J. Am. Coll. Cardiol., 2008, 52, 428-434.
8. Nieminen, M.S.; Brutsaert, D.; Dickstein, K.; Drexler, H.; Follath, F.; Harjola, V.P.; Hochadel, M.; Komajda, M.; Lassus, J.; Lopez-Sendon, J.L.; Ponikowski, P.; Tavazzi, L. EuroHeart Survey Investigators; Heart Failure Association; European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur. Heart J., 2006, 27, 2725-2736.
9. Ahmed, A.; Allman, R.M.; Fonarow, G.C.; Love, T.E.; Zannad, F.; Dell'italia, L.J.; White, M.; Gheorghiade, M. Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J. Card. Fail., 2008, 14, 211-218. (Pubitemid 351434595)
10. Yancy, C.W.; Lopatin, M.; Stevenson, L.W.; De Marco T.; Fonarow, G.C. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J. Am. Coll. Cardiol., 2006, 47, 76-84.
11. Fonarow, G.C.; Stough, W.G.; Abraham, W.T.; Albert, N.M.; Gheorghiade, M.; Greenberg, B.H.; O'Connor, C.M.; Sun, J.L.; Yancy, C.W.; Young, J.B. OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J. Am. Coll. Cardiol., 2007, 50, 768-777.
12. Adams, K.F. Jr.; Fonarow, G.C.; Emerman, C.L.; LeJemtel, T.H.; Costanzo, M.R.; Abraham, W.T.; Berkowitz, R.L.; Galvao, M.; Horton, D.P. For the ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompenated Heart Failure National Registry (ADHERE). Am. Heart J., 2005, 149, 209-216.
13. Fonarow, G.C.; Abraham, W.T.; Albert, N.M.; Stough, W.G., Gheorghiade, M.; Greenberg, B.H.; O'Connor, C.M.; Pieper, K.; Sun, J.L.; Yancy, C.; Young, J.B. OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA., 2007, 297, 61-70.
14. Bundkirchen, A.; Scwinger, R.H.G. Epidemiology and economic burden of chronic heart failure. Eur. Heart J. Suppl., 2004, 6, D57-D60.
15. Fonarow, G.C. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev. Cardiovasc. Med., 2003, 4, S21-30.
16. Fonarow, G.C.; Abraham, W.T.; Albert, N.M.; Gattis, W.A.; Gheorghiade, M.; Greenberg, B.; O'Connor, C.M.; Yancy, C.W.; Young. Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design. J. Am. Heart J., 2004, 148, 43-51.
17. Gheorghiade, M.; Abraham, W.T.; Albert, N.M.; Greenberg, B.H.; O'Connor, C.M.; She, L., Stough, W.G.; Yancy, C.W.; Young, J.B.; Fonarow, G.C. OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA., 2006, 296, 2217-2226.
18. Zannad, F.; Mebazaa, A.; Juillière, Y.; Cohen-Solal, A.; Guize, L.; Alla, F.; Rougé, P.; Blin, P.; Barlet, M.H.; Paolozzi, L.; Vincent, C.; Desnos, M.; Samii, K. EFICA Investigators. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur. J. Heart Fail., 2006, 8, 697-705. (Pubitemid 44754746)
19. Rudiger, A.; Harjola, V.P.; Müller, A.; Mattila, E.; Säila, P.; Nieminen, M.; Follath, F. Acute heart failure: clinical presentation, one-year mortality and prognostic factors. Eur. J. Heart Fail., 2005, 7, 662-670. (Pubitemid 40733001)
20. Reynolds, H.R.; Hochman, J.S. Cardiogenic shock: current concepts and improving outcomes. Circulation, 2008, 117, 686-697.
21. Brater, D.C. Diuretic therapy. N. Engl. J. Med., 1998, 339, 387-395.
22. Dikshit, K.; Vyden, J.K.; Forrester, J.S.; Chatterjee, K.; Prakash, R.; Swan, H.J. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N. Engl. J. Med., 1973, 288, 1087-1090.
23. Emerman, C.L.; Marco, T.D.; Costanzo, M.R.; Peacock, W.F. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE Registry. J. Cardiac. Fail., 2004, 10, S116.
24. Iyengar, S.; Abraham, W.T. Diuretics for the treatment of acute decompensated heart failure. Heart Fail. Rev., 2007, 12, 125-130. (Pubitemid 46916958)
25. Shin, D.D.; Brandimarte, F.; De Luca, L.; Sabbah, H.N.; Fonarow, G.C.; Filippatos, G.; Komajda, M.; Gheorghiade, M. Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am. J. Cardiol., 2007, 99, 4A-23A. (Pubitemid 46099035)
26. Francis, G.S.; Siegel, R.M.; Goldsmith, S.R.; Olivari, M.T.; Levine, T.B.; Cohn, J.N. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohormonal axis. Ann. Intern. Med., 1985, 103, 1-6.
27. Cooper, H.A.; Dries, D.L.; Davis, C.E.; Shen, Y.L.; Domanski, M.J. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation, 1999, 100, 1311-1315. (Pubitemid 29440124)
28. Domanski, M.; Norman, J.; Pitt, B.; Haigney, M.; Hanlon, S.; Peyster, E. Studies of Left Ventricular Dysfunction. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J. Am. Coll. Cardiol., 2003, 42, 705-708.
29. Hasselblad, V.; Gattis Stough, W.; Shah, M.R., Lokhnygina, Y.; O'Connor, C.M.; Califf, R.M.; Adams, K.F. Jr. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. J. Card. Fail., 2007, 9, 1064-1069.
30. Finley 4th, J.; Konstam, M.A.; Udelson, J.E. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation., 2008, 118, 410-421.
31. Ali, F.; Guglin, M.; Vaitkevicius, P.; Ghali, J.K. Therapeutic potential of vasopressin receptor antagonists. Drugs, 2007, 67, 847-858. (Pubitemid 46607386)
32. Gheorghiade, M.; Abraham, W.T.; Albert, N.M.; Gattis Stough, W.; Greenberg, B.H.; O'Connor, C.M.; She, L.; Yancy, C.W.; Young, J.; Fonarow, G.C. OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur. Heart J., 2007, 28, 980-988.
33. Yamamura, Y.; Nakamura, S.; Itoh, S., Hirano, T.; Onogawa, T.; Yamashita, T.; Yamada, Y.; Tsujimae, K.; Aoyama, M.; Kotosai, K.; Ogawa, H.; Yamashita, H.; Kondo, K.; Tominaga, M.; Tsujimoto, G.; Mori, T. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J. Pharmacol. Exp. Ther., 1998, 287, 860-867. (Pubitemid 29131593)
34. Hirano, T.; Yamamura, Y.; Nakamura, S.; Onogawa, T.; Mori, T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J. Pharmacol. Exp. Ther., 2000, 292, 288-294. (Pubitemid 30026383)
35. Shoaf, S.E.; Wang, Z.; Bricmont, P.; Mallikaarjun, S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J. Clin. Pharmacol., 2007, 47, 1498-1507.
36. Hauptman, P.J.; Zimmer, C.; Udelson, J.; Shoaf, S.E.; Mallikaarjun, S.; Bramer, S.L.; Orlandi, C. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J. Cardiovasc. Pharmacol., 2005, 46, 609-614. (Pubitemid 41527753)
37. Gheorghiade, M.; Niazi, I.; Ouyang, J.; Czerwiec, F.; Kambayashi, J.; Zampino, M. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation, 2003, 107, 2690-2696. (Pubitemid 36667242)
38. Udelson, J.; Orlandi, C.; Ouyang, J.; Krasa, H.; Zimmer, C.; Frivold, G.; Haught, W.; Meymandi, S.; Wedge, P.; Konstam, M. Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients with Symptomatic Heart Failure and Systolic Dysfunction: The ECLIPSE international, multicenter, randomized, placebo-controlled trial. J. Cardiac. Fail., 2007, 13, 793.
39. Gheorghiade, M.; Gattis, W.A.; O'Connor, C.M.; Adams, K.F. Jr; Elkayam, U.; Barbagelata, A.; Ghali, J.K.; Benza, R.L.; McGrew, F.A.; Klapholz, M.; Ouyang, J.; Orlandi, C.; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA, 2004, 291, 1963-1971.
40. Rossi, J.; Bayram, M.; Udelson, J.E.; Lloyd-Jones, D.; Adams, K.F.; Oconnor, C.M.; Stough, W.G.; Ouyang, J.; Shin, D.D.; Orlandi, C.; Gheorghiade, M. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (ACTIV in CHF) trial. Acute Card. Care, 2007, 9, 82-86. (Pubitemid 46955230)
41. Gheorghiade, M.; Konstam, M.A.; Burnett, J.C. Jr; Grinfeld, L.; Maggioni, A.P.; Swedberg, K.; Udelson, J.E.; Zannad, F.; Cook, T.; Ouyang, J.; Zimmer, C.; Orlandi, C. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA, 2007, 297, 1332-1343.
42. Konstam, M.A.; Gheorghiade, M.; Burnett, J.C. Jr; Grinfeld, L.; Maggioni, A.P.; Swedberg, K.; Udelson, J.E.; Zannad, F.; Cook, T.; Ouyang, J.; Zimmer, C.; Orlandi, C.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA, 2007, 297, 1319-1331.
43. Goldsmith S.R.; Elkayam, U.; Haught,W.H.; Barve, A.; He, W. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. Card. Fail., 2008, 14, 641-647.
44. Abraham, W.T.; Shamshirsaz, A.A.; McFann, K.; Oren, R.M.; Schrier, R.W. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J. Am. Coll. Cardiol., 2006, 47, 1615-1621.
45. Metra, M.; Nodari, S.; Parrinello, G.; Bordonali, T.; Bugatti, S.; Danesi, R.; Fontanella, B.; Lombardi, C.; Milani, P.; Verzura, G.; Cotter, G.; Dittrich, H.; Massie, B.M.; Dei Cas, L. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur. J. Heart Fail., 2008, 10, 188-195.
46. Smith, G.L.; Lichtman, J.H.; Bracken, M.B.; Shlipak, M.G.; Phillips, C.O.; DiCapua, P.; Krumholz, H.M. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J. Am. Coll. Cardiol., 2006, 47, 1987-1996.
47. Forman, D.E.; Butler, J.; Wang, Y.; Abraham, W.T.; O'Connor, C.M.; Gottlieb, S.S.; Loh, E.; Massie, B.M.; Rich, M.W.; Stevenson, L.W.; Young, J.B.; Krumholz, H.M. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol., 2004, 43, 61-67. (Pubitemid 38045917)
48. Fredholm, B.B.; Chen, J.F.; Masino, S.A.; Vaugeois, J.M. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 385-412.
49. Vallon, V.; Muhlbauer, B.; Osswald, H. Adenosine and kidney function. Physiol. Rev., 2006, 86, 901-940.
50. Modlinger, P.S.; Welch, W.J. Adenosine A1 receptor antagonists and the kidney. Curr. Opin. Nephrol. Hypertens., 2003, 12, 497-502.
51. Gottlieb, S.S.; Brater, D.C.; Thomas, I.; Havranek, E.; Bourge, R.; Goldman, S.; Dyer, F.; Gomez, M.; Bennett, D.; Ticho, B.; Beckman, E.; Abraham, W.T. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation, 2002, 105, 1348-1353.
52. Greenberg, B.; Thomas, I.; Banish, D.; Goldman, S.; Havranek, E.; Massie, B.M.; Zhu, Y.; Ticho, B.; Abraham, W.T. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure results of a placebo-controlled, dose-escalation study. J. Am. Coll. Cardiol., 2007, 50, 600-606.
53. Kalk, P.; Eggert, B.; Relle, K.; Godes, M.; Heiden, S.; Sharkovska, Y.; Fischer, Y.; Ziegler, D.; Bielenberg, G.W.; Hocher, B. The adenosine A(1) receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br. J. Pharmacol., 2007, 151, 1025-1032. (Pubitemid 47195534)
54. Mitrovic, V.; Seferovic, P.; Dodic, S.; Krotin, M.; Neskovic, A.; Dickstein, K.; Devoogd, H.; Böcker, C.; Ziegler, D.; Godes, M.; Nakov, R.; Essers, H.; Essers, H.; Verboom, C.; Hocher B. Cardiorenal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure. Circulation Heart Fail., 2009 (in press).
55. Givertz, M.M.; Massie, B.M.; Fields, T.K.; Pearson, L.L.; Dittrich, H.C.; CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J. Am. Coll. Cardiol., 2007, 50, 1551-1560.
56. Dittrich, H.C.; Gupta, D.K.; Hack, T.C.; Dowling, T.; Callahan, J.; Thomson, S. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J. Card. Fail., 2007, 13, 609-617. (Pubitemid 47513547)
57. Dunwiddie, T.V.; Worth, T. Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J. Pharmacol. Exp. Ther., 1982, 220, 70-76. (Pubitemid 12219290)
58. Cotter, G.; Dittrich, H.C.; Weatherley, B.D.; Bloomfield, D.M.; O'Connor, C.M.; Metra, M.; Massie, B.M. Protect Steering Committee, Investigators, and Coordinators. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J. Card. Fail,. 2008, 14, 631-640.
59. Vallon, V.; Miracle, C.; Thomson, S. Adenosine and kidney function: potential implications in patients with heart failure. Eur. J. Heart Fail. 2008, 10, 176-187.
60. Hollenberg, S.M. Vasodilators in acute heart failure. Heart Fail. Rev., 2007, 12, 143-147.
61. Bart, B.A.; Shaw, L.K.; McCants, C.B. Jr; Fortin, D.F.; Lee, K.L.; Califf, R.M.; O'Connor, C.M. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or non-ischemic cardiomyopathy. J. Am. Coll. Cardiol., 1997, 30, 1002-1008.
62. Treasure, C.B.; Vita, J.A.; Cox, D.A.; Fish, R.D.; Gordon, J.B.; Mudge, G.H.; Colucci, W.S.; St. John Sutton, M.G.; Selwyn, A.P.; Alexander, W.; Ganz, P. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation, 1990, 81, 772-779. (Pubitemid 20090372)
63. Cohn, J.N.; Franciosa, J.A.; Francis, G.S.; Archibald, D.; Tristani, F.; Fletcher, R.; Montero, A.; Cintron, G.; Clarke, J.; Hager, D.; Saunders, R.; Cobb, F.; Smith, R.; Loeb, H.; Settle, H. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N. Engl. J. Med., 1982, 306, 1129-1135.
64. Sackner-Bernstein, J.D.; Skopicki, H.A.; Aaronson, K.D. Risk of worsening renal function with nesiritide in patient with acutely decompensated heart failure. Circulation, 2005, 111, 1487-1491.
65. Felker, G.M.; Benza, R.L.; Chandler, A.B.; Leimberger, J.D.; Cuffe, M.S.; Califf, R.M.; Gheorghiade, M.; O'Connor, C.M.; OPTIME-CHF Investigators. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J. Am. Coll. Cardiol., 2003, 41, 997-1003.
66. Beohar, N.; Erdogan, A.K.; Lee, D.C.; Sabbah, H.N.; Kern, M.J.; Teerlink, J.; Bonow, R.O.; Gheorghiade, M. Acute heart failure syndromes and coronary perfusion. J. Am. Coll. Cardiol., 2008, 52, 13-16. (Pubitemid 351852938)
67. Lee, C.Y.; Burnett, J.C. Jr. Natriuretic peptides and therapeutic applications. Heart Fail. Rev., 2007, 12, 131-142.
68. Potter, L.R.; Abbey-Hosch, S.; Dickey, D.M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endoc. Rev., 2006, 27, 47-72.
69. Forssmann, W.; Meyer, M.; Forssmann, K. The renal urodilatin system: clinical implications. Cardiovasc. Res., 2001, 51, 450-462. (Pubitemid 32718593)
70. Cody, R.J.; Atlas, S.A.; Laragh, J.H.; Kubo, S.H.; Covit, A.B.; Ryman, K.S.; Shaknovich, A.; Pondolfino, K.; Clark, M.; Camargo, M.J. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J. Clin. Invest., 1986, 78, 1362-1374. (Pubitemid 17181577)
71. Suwa, M.; Seino, Y.; Nomachi, Y.; Matsuki, S.; Funahashi, K. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ. J., 2005, 69, 283-290.
72. Hata, N.; Seino, Y.; Tsutamoto, T.; Hiramitsu, S.; Kaneko, N.; Yoshikawa, T.; Yokoyama, H.; Tanaka, K.; Mizuno, K.; Nejima, J.; Kinoshita, M. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ. J., 2008, 72, 1787-1793.
73. Nomura, F.; Kurobe, N.; Mori, Y.; Hikita, A.; Kawai, M.; Suwa, M.; Okutani, Y. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ. J., 2008, 72, 1777-1786.
74. Keating, G.M.; Goa, K.L. Nesiritide: a review of its use in acute decompensated heart failure. Drugs, 2003, 63, 47-70. (Pubitemid 36132513)
75. Abraham, W.T.; Lowes, B.D.; Ferguson, D.A.; Odom, J.; Kim, J.K.; Robertson, A.D.; Bristow, M.R.; Schrier, R.W. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J. Card. Fail., 1998, 4, 37-44.
76. Mills, R.M.; LeJemtel, T.H.; Horton, D.P.; Liang, C.; Lang, R.; Silver, M.A.; Lui, C.; Chatterjee, K. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. J. Am. Coll. Cardiol., 1999, 34, 155-162.
77. Colucci, W.S.; Elkayam, U.; Horton, D.P.; Abraham, W.T.; Bourge, R.C.; Johnson, A.D.; Wagoner, L.E.; Givertz, M.M.; Liang, C.S.; Neibaur, M.; Haught, W.H.; LeJemtel, T.H. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N. Engl. J. Med., 2000, 343, 246-253. (Pubitemid 30490392)
78. Burger, A.J.; Horton, D.P.; LeJemtel, T.; Ghali, J.K.; Torre, G.; Dennish, G.; Koren, M.; Dinerman, J.; Silver, M.; Cheng, M.L.; Elkayam, U.; Prospective randomized evaluation of cardiac ectopy with dobutamine or natrecor therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J., 2002, 144, 1102-1108.
79. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA, 2002, 287, 1531-1540.
80. Yancy, C.W.; Singh, A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial). Am. J. Cardiol., 2006, 98, 226-229. (Pubitemid 43975501)
81. Yancy, C.W.; Krum, H.; Massie, B.M.; Silver, M. A.; Stevenson, L.W.; Cheng, M.; Kim, S.S.; Evans, R.; the FUSION II Investigators. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ. Heart Fail., 2008, 1, 9-16.
82. Witteles, R.M.; Kao, D.; Christopherson, D.; Matsuda, K.; Vagelos, R.H.; Schreiber, D.; Fowler, M.B. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebocontrolled clinical trial. J. Am. Coll. Cardiol., 2007, 50, 1835-1840.
83. Mitrovic, V.; Lüss, H.; Nitsche, K.; Forssmann, K.; Maronde, E.; Fricke, K.; Forssmann, W.G.; Meyer, M. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am. Heart J., 2005, 150, 1239. (Pubitemid 41773529)
84. Mitrovic, V.; Seferovic, P.M.; Simeunovic, D.; Ristic, A.D.; Miric, M.; Moiseyev, V.S.; Kobalava, Z.; Nitsche, K.; Forssmann, W.G.; Lüss, H.; Meyer, M. Haemodynamic and clinical effects of ularitide in decompensated heart failure Eur. Heart J., 2006, 27, 2823-2832. (Pubitemid 44871466)
85. Lüss, H.; Mitrovic, V.; Seferovic, P.M.; Simeunovic, D.; Ristić, A.D.; Moiseyev, V.S.; Forssmann, W.G.; Hamdy, A.M.; Meyer, M. Renal effects of ularitide in patients with decompensated heart failure. Am. Heart J., 2008, 155, 1012.e1. (Pubitemid 351721023)
86. Coletta, A.P.; Cleland, J.G.; Cullington, D.; Clark, A.L. Clinical trials update from Heart Rhythm 2008 and Heart Failure 2008: ATHENA, URGENT, INH study, HEART and CK-1827452. Eur. J. Heart Fail., 2008, 10, 917-920.
87. Schulz, R.; Rassaf, T.; Massion, P.B.; Kelm, M.; Balligand, J.L. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol. Ther., 2005, 108, 225-256. (Pubitemid 41691866)
88. Hare, J.M.; Stamler, J.S. NO/redox disequilibrium in the failing heart and cardiovascular system. J. Clin. Invest., 2005, 115, 509-517. (Pubitemid 40322220)
89. Evgenov, O.V.; Pacher, P.; Schmidt, P.M.; Haskó, G.; Schmidt, H.H.; Stasch, J.P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov., 2006, 5, 755-768. (Pubitemid 44323702)
90. Stasch, J.P.; Schmidt, P.; Alonso-Alija, C.; Apeler, H.; Dembowsky, K.; Haerter, M.; Heil, M.; Minuth, T.; Perzborn, E.; Pleiss, U.; Schramm, M.; Schroeder, W.; Schröder, H.; Stahl, E.; Steinke, W.; Wunder, F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br. J. Pharmacol., 2002, 136, 773-783. (Pubitemid 34785720)
91. Frey, R.; Muck, W.; Unger, S.; Artmeier-Brandt, U.; Weimann, G.; Wensing, G. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J. Clin. Pharmacol., 2008, 48, 1400-1410.
92. Lapp, H.; Mitrovic, V.; Franz, N.; Heuer, H.; Buerke, M.; Wolfertz, J.; Mueck, W.; Unger, S.; Wensing, G.; Frey, R. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation, 2009, 119, 2781-2788.
93. Goldberg, R.J.; Samad, N.A.; Yarzebski, J.; Gurwitz, J.; Bigelow, C.; Gore, J.M. Temporal trends in cardiogenic shock complicating myocardial infarction. N. Engl. J. Med., 1999, 340, 1162-1168. (Pubitemid 29177875)
94. Reynolds, H.R.; Hochman, J.S. Cardiogenic shock: current concepts and improving outcomes. Circulation, 2008, 117, 686-697.
95. Cotter, G.; Kaluski, E.; Blatt, A.; Milovanov, O.; Moshkovitz, Y.; Zaidenstein, R.; Salah, A.; Alon, D.; Michovitz, Y.; Metzger, M.; Vered, Z.; Golik, A. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation, 2000, 101, 1358-1361.
96. Cotter, G.; Kaluski, E.; Milo, O.; Blatt, A.; Salah, A.; Hendler, A.; Krakover, R.; Golick, A.; Vered, Z. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock. A prospective randomized study. Eur. Heart J., 2003, 24, 1287-1295.
97. Dzavík, V.; Cotter, G.; Reynolds, H.R.; Alexander, J.H.; Ramanathan, K.; Stebbins, A.L.; Hathaway, D.; Farkouh, M.E.; Ohman, E.M.; Baran, D.A.; Prondzinsky, R.; Panza, J.A.; Cantor, W.J.; Vered, Z.; Buller, C.E.; Kleiman, N.S.; Webb, J.G.; Holmes, D.R.; Parrillo, J.E.; Hazen, S.L.; Gross, S.S.; Harrington, R.A.; Hochman, J.S.; SHould we inhibit nitric Oxide synthase in Cardiogenic shocK 2 (SHOCK-2) investigators. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur. Heart J., 2007, 28, 1109-1116.
98. The TRIUMPH Investigators. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA, 2007, 297, 1657-1666.
99. Rich, S.; McLaughlin, V.V. Endothelin receptor blockers in cardiovascular disease. Circulation, 2003, 108, 2184-2190. (Pubitemid 37363032)
100. Teerlink JR. The role of endothelin in the pathogenesis of heart failure. Curr. Cardiol. Rep., 2002, 4, 206-212.
101. Aronson, D.; Burger, A.J. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am. J. Cardiol., 2003, 91, 245-248.
102. Torre-Amione, G.; Young, J.B.; Colucci, W.S.; Lewis, B.S.; Pratt, C.; Cotter, G.; Stangl, K.; Elkayam, U.; Teerlink, J.R.; Frey, A.; Rainisio, M.; Kobrin, I. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol., 2003, 42, 140-147.
103. O'Connor, C.M.; Gattis, W.A.; Adams, K.F. Jr; Hasselblad, V.; Chandler, B.; Frey, A.; Kobrin, I.; Rainisio, M.; Shah, M.R.; Teerlink, J.; Gheorghiade, M. Randomized Intravenous TeZosentan Study-4 Investigators. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J. Am. Coll. Cardiol., 2003, 41, 1452-1457.
104. Coletta, A.P.; Cleland, J.G. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur. J. Heart Fail., 2001, 3, 747-750.
105. Kaluski, E.; Kobrin, I.; Zimlichman, R.; Marmor, A.; Krakov, O.; Milo, O.; Frey, A.; Kaplan, S.; Krakover, R.; Caspi, A.; Vered, Z.; Cotter, G. RITZ-5: randomized intravenous TeZosentan (an endothelin- A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, doubleblind, placebo-controlled study. J. Am. Coll. Cardiol., 2003, 41, 204-210.
106. Gheorghiade, M.; De Luca, L.; Bonow, R.O. Neurohormonal Inhibition in heart failure: insights from recent clinical trials. Am. J. Cardiol., 2005, 96, 3L-9L.
107. McMurray, J.J.; Teerlink, J.R.; Cotter, G.; Bourge, R.C.; Cleland, J.G.; Jondeau, G.; Krum, H.; Metra, M.; O'Connor, C.M.; Parker, J.D.; Torre-Amione, G.; van Veldhuisen, D.J.; Lewsey, J.; Frey, A.; Rainisio, M.; Kobrin, I.; VERITAS Investigators. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA., 2007, 298, 2009-2019.
108. van der Westhuizen, E.T.; Halls, M.L.; Samuel, C.S.; Bathgate, R.A.; Unemori, E.N.; Sutton, S.W.; Summers, R.J. Relaxin family peptide receptors - from orphans to therapeutic targets. Drug Discov. Today., 2008, 13, 640-651.
109. Samuel, C.S.; Du, X.J.; Bathgate, R.A.; Summers, R.J. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. Pharmacol. Ther., 2006, 112, 529-552.
110. Dschietzig, T.; Richter, C.; Bartsch, C.; Laule, M.; Armbruster, F.P.; Baumann, G.; Stangl, K. The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 2001, 15, 2187-2195. (Pubitemid 32927936)
111. Dschietzig, T.; Teichman, S.; Unemori, E.; Wood, S.; Boehmer, J.; Richter, C.; Baumann, G.; Stangl, K. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J. Cardiac. Fail., 2009, 15, 182-190.
112. Teerlink, J.R.; Metra, M.; Felker, G.M.; Ponikowski, P.; Voors, A.A.; Weatherley, B.D.; Marmor, A.; Katz, A.; Grzybowski, J.; Unemori, E.; Teichman, S.L.; Cotter, G. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet, 2009, 373, 1429-1439.
113. Staessen, J.A.; Li, Y.; Richart, T. Oral renin inhibiyors. Oral renin inhibitors. Lancet, 2006, 368, 1449-1456.
114. Jensen, C.; Herold, P.; Brunner, H.R. Aliskiren: the first renin inhibitor for clinical treatment. Nat. Rev. Drug Disc. 2008, 7, 399-410.
115. Nguyen, G.; Delarue, F.; Burcklé, C.; Bouzhir, L.; Giller, T.; Sraer, J.D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest., 2002, 109, 1417-1427. (Pubitemid 34596167)
116. Jan Danser, A.H.; Batenburg, W.W.; van Esch, J.H. Prorenin and the (pro)renin receptor - an update. Nephrol. Dial. Transplant., 2007, 22, 1288-1292.
117. McMurray, J.J.V.; Pitt, B.; Latini, R.; Maggioni, A.P.; Solomon, S.D.; Keefe, D.L.; Ford, J.; Verma, A.; Lewsey, J.; for the Aliskiren Obsrevation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail., 2008, 1, 17-24.
118. Swedberg, K.E.P.; Kjekshus, J.; Wilhelmsen, L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation., 1990, 82, 1730-1736. (Pubitemid 20367976)
119. Williams, J.S.; Williams, G.H. 50th Anniversary of aldosterone. J Clin Endocrinol Metab., 2003, 88, 2364-2372.
120. Pitt, B.; Zannad, F.; Remme, W.J.; Cody, R.; Castaigne, A.; Perez, A.; Palensky, J.; Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med., 1999, 341, 709-717.
121. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med., 2003, 348, 1309-1321. (Pubitemid 36384098)
122. Chai, W.; Garrelds, I.M.; de Vries, R.; Batenburg, W.W.; van Kats, J.P.; Danser, A.H. Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension, 2005, 46, 701-706. (Pubitemid 43186741)
123. Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol. Cell Endocrinol., 2004, 217, 75-79. (Pubitemid 38596631)
124. Mizuno, Y.; Yoshimura, M.; Yasue, H.; Sakamoto, T.; Ogawa, H.; Kugiyama, K.; Harada, E.; Nakayama, M.; Nakamura, S.; Ito, T.; Shimasaki, Y.; Saito, Y.; Nakao, K. Aldosterone production is activated in failing ventricle in humans. Circulation, 2001, 103, 72-77. (Pubitemid 32050438)
125. Tsybouleva, N.; Zhang, L.; Chen, S.; Patel, R.; Lutucuta, S.; Nemoto, S.; DeFreitas, G.; Entman, M.; Carabello, B.A.; Roberts, R.; Marian, A.J. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation, 2004, 109, 1284-1291.
126. Fiebeler, A.; Nussberger, J.; Shagdarsuren, E.; Rong, S.; Hilfenhaus, G.; Al-Saadi, N.; Dechend, R.; Wellner, M.; Meiners, S.; Maser-Gluth, C.; Jeng, A.Y.; Webb, R.L.; Luft, F.C.; Muller, D.N. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation, 2005, 111, 3087-3094. (Pubitemid 40847786)
127. Mulder, P.; Mellin, V.; Favre, J.; Vercauteren, M.; Remy-Jouet, I.; Monteil, C.; Richard, V.; Renet, S.; Henry, J.P.; Jeng, A.Y.; Webb, R.L.; Thuillez, C. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008,29,2171-2179.
128. Parissis, J.T.; Farmakis, D.; Nieminen, M. Classical inotropes and new cardiac enhancers. Heart Fail. Rev., 2007, 12, 149-156. (Pubitemid 46916961)
129. Elkayam, U.; Tasissa, G.; Binanay, C.; Stevenson, L.W.; Gheorghiade, M.; Warnica, J.W.; Young, J.B.; Rayburn, B.K.; Rogers, J.G.; DeMarco, T.; Leier, C.V. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am. Heart J., 2007, 153, 98-104. (Pubitemid 44880871)
130. O'Connor, C.M.; Gattis, W.A.; Uretsky, B.F.; Adams, K.F. Jr.; McNulty, S.E.; Grossman, S.H.; McKenna, W.J.; Zannad, F.; Swedberg, K.; Gheorghiade, M.; Califf, R.M. . Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart J., 1999, 138, 78-86.
131. Cleland, J.G.; Pennell, D.J.; Ray, S.G.; Coats, A.J.; Macfarlane, P.W.; Murray, G.D.; Mule, J.D.; Vered, Z.; Lahiri, A.; Carvedilol hibernating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of ejection fraction response to carvediol in patients with heart failure (CHRISTMAS trial): randomized control trial. Lancet, 2003, 362, 14-21.
132. Abraham, W.T.; Adams, K.F.; Fonarow, G.C.; Costanzo, M.R.; Berkowitz, R.L.; LeJemtel, T.H.; Cheng, M.L.; Wynne, J.; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: analysis from the acute decompensated heart failure national registry (ADHERE). J. Am. Coll. Cardiol., 2005, 46, 57-64.
133. Cuffe, M.S.; Califf, R.M.; Adams, K.F. Jr.; Benza, R.; Bourge, R.; Colucci, W.S.; Massie, B.M.; O'Connor, C.M.; Pina, I.; Quigg, R.; Silver, M.A.; Gheorghiade, M.; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Effects of short-term, intravenous milrinone on acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA, 2002, 287, 1541-1547.
134. Burger, A.J.; Elkayam, U.; Neibaur, M.T.; Haught, H.; Ghali, J.; Horton, D.P.; Aronson, D. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am. J. Cardiol., 2001, 88, 35-39. (Pubitemid 32553889)
135. Thackray, S.; Easthaugh, J.; Freemantle, N.; Cleland, J.G. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur. J. Heart Fail., 2002, 4, 515-529.
136. Amsallem, E.; Kasparian, C.; Haddour, G.; Boissel, J.P.; Nony, P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst. Rev. 2005, 1, CD002230.
137. Tamargo, J.; Caballero, R.; Gómez, R.; Barana, A.; Amorós, I.; Delpón, E. Investigational positive inotropic agents for acute heart failure. Cardiovasc. Hematol. Disord. Drug Targets, 2009, 9, 193-205.
138. Haikala, H.; Nissinen, E.; Etemadzadeh, E.; Levijoki, J.; Linden, I.B. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J. Cardiovasc. Pharmacol., 1995, 25, 794-801.
139. Antoniades, C.; Tousoulis, D.; Koumallos, N.; Marinou, K.; Stefanadis. Levosimendan: beyond its simple inotropic effect in heart failure. C. Pharmacol. Ther. 2007, 114, 184.
140. De Luca, L.; Colucci, W.S.; Nieminen, M.S.; Massie, B.M.; Gheorghiade, M. Evidence-based use of levosimendan in different clinical settings. Eur. Heart J., 2006, 27, 1908-1920. (Pubitemid 44297362)
141. Sonntag, S.; Sundberg, S.; Lehtonen, L.A.; Kleber, F.X. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J. Am. Coll. Cardiol., 2004, 43, 2177-2182.
142. Yokoshiki, H.; Sperelakis, N. Vasodilating mechanisms of levosimendan. Cardiovasc. Drugs Ther., 2003, 17, 111-113.
143. Antila, S.; Sundberg, S.; Lehtonen, L.A. Clinical pharmacology of levosimendan. Clin. Pharmacokinet., 2007, 46, 535-552.
144. Kyrzopoulos, S.; Adamopoulos, S.; Parissis, J.T.; Rassias, J.; Kostakis, G.; Iliodromitis, E.; Degiannis, D.; Kremastinos, D.T. Levosimendan reduces plasma B-type natriuretic peptide and interleukin-6, and improves central hemodynamics in severe heart failure patients. Int. J. Cardiol., 2005, 99, 409-413. (Pubitemid 40363991)
145. Nicklas, J.M.; Monsur, J.C.; Bleske, B.E. Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am. J. Cardiol., 1999, 83 (suppl 2), 12-15.
146. Follath, F.; Cleland, J.G.; Just, H.; Papp, J.G.; Scholz, H.; Peuhkurinen, K.; Harjola, V.P.; Mitrovic, V.; Abdalla, M.; Sandell, E.P.; Lehtonen, L.; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet, 2002, 360, 196-202.
147. Moiseyev, V.S.; Põder, P.; Andrejevs, N.; Ruda, M.Y.; Golikov, A.P.; Lazebnik, L.B., Kobalava, Z.D.; Lehtonen, L.A.; Laine, T.; Nieminen, M.S.; Lie, K.I.; RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur. Heart J., 2002, 23, 1422-1432. (Pubitemid 36285574)
148. Zairis, M.N.; Apostolatos, C.; Anastasiadis, P. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results from the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure Study (CASINO). (Abstract). J. Am. Coll. Cardiol., 2004, 43, 206A.
149. Mebazaa, A.; Nieminen, M.S.; Packer, M.; Cohen-Solal, A.; Kleber, F.X.; Pocock, S.J.; Thakkar, R.; Padley, R.J.; Põder, P.; Kivikko, M.; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA, 2007, 297, 1883-1891. (Pubitemid 46707842)
150. Packer, M.; Colucci, W.S.; Fisher, L.; Massie, B.M.; Teerlink, J.R.; Young, J.B.; Garrat, C.J. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure results with levosimendan in the REVIVE-1 study. J. Card. Fail., 2003, 9, S61.
151. Johansson, S.; Apajasalo, M.; Sarapohja, T.; Garratt, C. Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study [abstract]. Crit. Care, 2004, 8, P88.
152. Packer, M. The Randomized multicenter EValuation of Intravenous leVosimendan Efficacy-2 (REVIVE-2) trial. Late-breaking Clinical Trials. American Heart Association, Annual Scientific Session 2005, 13.
153. Micheletti, R.; Mattera, G.G.; Rocchetti, M.; Schiavone, A.; Loi, M.F.; Zaza, A.; Gagnol, R.J.; De Munari, S.; Melloni, P.; Carminati, P.; Bianchi, G.; Ferrari, P. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J. Pharmacol. Exp. Ther., 2002, 303, 592-600. (Pubitemid 35231230)
154. Khan, H.; Metra, M.; Blair, J.E.; Vogel, M.; Harinstein, M.E.; Filippatos, G.S.; Sabbah, H.N.; Porchet, H.; Valentini, G.; Gheorghiade, M. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail. Rev. 2009, Feb 24. [Epub ahead of print]
155. Adamson, P.B.; Vanoli, E.; Mattera, G.G.; Germany, R.; Gagnol, J.P.; Carminati, P.; Schwartz, P.J. Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure. J. Cardiovasc. Pharmacol., 2003, 42, 169-173.
156. Sabbah, H.N.; Imai, M.; Cowart, D.; Amato, A.; Carminati, P.; Gheorghiade, M. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Am. J. Cardiol., 2007, 99, 41A-46A. (Pubitemid 46096882)
157. Mattera, G.G.; Lo Giudice, P.; Loi, F.M.; Vanoli, E.; Gagnol, J.P.; Borsini, F.; Carminati, P. Istaroxime: a new lusoinotropic agent for heart failure. Am. J. Cardiol., 2007, 99, S33.
158. Ghali, J.K.; Smith, W.B.; Torre-Amione, G.; Haynos, W.; Rayburn, B.K.; Amato, A.; Zhang, D.; Cowart, D.; Valentini, G.; Carminati, P.; Gheorghiade, M. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure and reduced systolic function. J. Am. Coll. Cardiol., 2007, 99, 47A. (Pubitemid 46096883)
159. Gheorghiade, M.; Blair, J.E.; Filippatos, G.S.; Macarie, C.; Ruzyllo, W.; Korewicki, J.; Bubenek-Turconi, S.I.; Ceracchi, M.; Bianchetti, M.; Carminati, P.; Kremastinos, D.; Valentini, G.; Sabbah, H.N.; HORIZON-HF Investigators. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J. Am. Coll. Cardiol., 2008, 51, 2276-2285.
160. Shah, S.J.; Blair, J.E.; Filippatos, G.S.; Macarie, C.; Ruzyllo, W.; Korewicki, J.; Bubenek-Turconi, S.I.; Ceracchi, M.; Bianchetti, M.; Carminati, P.; Kremastinos, D; Grzybowski, J.; Valentini, G.; Sabbah, H.N.; Gheorghiade, M.; HORIZON-HF Investigators. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am. Heart J., 2009, 157, 1035-1041.
161. Solaro, R.J. CK-1827452, a sarcomere-directed cardiac myosin activator for acute and chronic heart disease. IDrugs., 2009, 12, 243-251.
162. Teerlink, J. R. novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail. Rev., 2009 Feb 21. [Epub ahead of print].
163. Malik, F., Elias, K.A.; Finer, J.T., Morgan, B.P.; Sakowicz, R.; Anderson, R.; Baliga, R.; Conn, L.; Cox, D.; Garard, M.; Hartman, J.; Irvine, J.; Kawas, R.; Kraynack, E.; Kuklov, A.; Lee, K.H.; Lu, P.; Muci, D.; Pierce, D.W.; Rodriguez, H.; Suehiro, I.; Sueoka, S.H.; Sylvester, S.; Tochimoto, T.; Valdez, C.; Wang, W.; Katori, T.; Kass, D.A.; Shen, Y.T.; Vatner, S.F.; Morgans, D.J. . Direct activation of cardiac myosin by CK-1827452 improves cardiac function in a dog heart failure model. J. Card. Fail., 2005, 11, S95.
164. Anderson, R.L.; Sueoka, S.H.; Lee, K.H.; Rodriguez, H.M.; Kawas, R.F.; Godinez, G.; Morgan, B.P.; Sakowicz, R.; Morgans, D.J.; Malik, F.; Elias, K.A. In vitro and in vivo efficacy of the cardiac myosin activator CK-1827452. J. Cardiac. Fail., 2006, 12, S86.
165. Shen, Y.; Zhang, Y.; Morgans, D.J.; Vatner, S.F.; Malik, F. A novel inotropic agent that activates cardiac myosin and increases cardiac contractility without increasing MVO2 in heart failure with left ventricular hypertrophy. J. Am. Coll. Cardiol., 2008, 51, A54.
166. Cleland, J.G.F.; McMurray, J.J.; Lang, C.C.; Clarke, C.P.; Neyses, L.; Saikali, K.G.; Lee, J.H.; Goldman, J.; Teerlink, J.R.; Malik, F. First clinical trial of the selective cardiac myosin activator, CK- 1827452, in heart failure: effect of dose and plasma concentration on systolic function. Eur. Heart J., 2008, 29, 299-314.
167. Senior, R.; Malik, F.; Saikali, K.; Lee, J.; Brand, G.; Wolff, A.A.; and the CY 1121 Investigators. The selective cardiac myosin activator, CK-1827452, increases systolic function in a concentrationdependent manner in patients with stable heart failure. J. Am. Coll. Cardiol., 2009, 53, A160.
168. Jerling, M.; Chew, T.; Escandon, R.; Lee, J.; Saikali, K.; Venables, E.; Clarke, C.; Malik, F.; Wolff, A. Oral bioavailability of the selective cardiac myosin activator CK-1827452: chronic oral inotropic therapy for heart failure? J. Cardiac. Fail., 2007, 13, S148.
169. Stanley, W.C.; Lopaschuk G.D.; Hall, J.L.; McCormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc. Res., 1997, 33, 243-257.
170. Lee, L.; Horowitz, J.; Frenneaux, M. Metabolic manipulation in ischaemic heart disease: a novel approach to treatment. Eur. Heart J., 2004, 25, 634-641. (Pubitemid 38579491)
171. Ashrafian, H.; Frenneaux, M.P.; Opie, L.H. Metabolic mechanisms in heart failure. Circulation., 2007, 116, 434-448.
172. Depre, C.; Vanoverschelde, J.L.; Taegtmeyer, H. Glucose for the heart. Circulation, 1999, 99, 578-588
173. Cole, P.L.; Beamer, A.D.; McGowan, N.; Cantillon C.O.; Benfell, K.; Kelly, R.A.; Hartley, L.H.; Smith, T.W.; Antman, E.M. Efficacy and safety of perhexiline maleate in refractory angina. Circulation, 1990, 81, 1260-1270.
174. Lee, L.; Campbell, R.; Scheuermann-Freestone, M.; Taylor, R.; Gunaruwan, P., Williams, L.; Ashrafian, H., Horowitz, J.; Fraser, A.G.; Clarke, K.; Frenneaux, M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation, 2005, 112, 3280-3288. (Pubitemid 43739373)
175. Inzucchi, S.E.; McGuire, D.K. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation, 2008, 117, 574-584.
176. Nikolaidis, L.A.; Mankad, S.; Sokos, G.G.; Miske, G.; Shah, A.; Elahi, D.; Shannon, R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004, 109, 962-965. (Pubitemid 38282847)
177. Thrainsdottir, I.; Malmberg, K.; Olsson, A.; Gutniak, M.; Rydén, L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab. Vasc. Dis. Res., 2004, 1, 40-43.
178. Sokos, G.G.; Nikolaidis, L.A., Mankad, S.; Elahi, D.; Shannon, R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail., 2006, 12, 694-699.
179. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium current". Pharmacol. Ther., 2008, 119, 326-339.
180. Hale, S.L.; Shryock, J.C.; Belardinelli, L.; Sweeney, M.; Kloner, R.A. Late sodium current inhibition as a new cardioprotective approach J. Mol. Cell. Cardiol., 2008, 44, 954-967.
181. Chandler, M.P.; Stanley, W.C.; Morita, H.; Suzuki, G.; Roth, B.A.; Blackburn, B.; Wolff, A.; Sabbah, H.N. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ. Res., 2002, 91, 278-280.
182. Sossalla, S.; Wagner, S.; Rasenack, E.C.; Ruff, H.; Weber, S.L.; Schöndube, F.A.; Tirilomis, T.; Tenderich, G.; Hasenfuss, G.; Belardinelli, L.; Maier, L.S. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts: role of late sodium current and intracellular ion accumulation. J. Mol. Cell. Cardiol., 2008, 45, 32-43.
183. Rousseau, M.F.; Van Eyll, C.; Van Mechelen, H.; Harlow, B.J.; Pouleur, H. Novel metabolic ranolazine selectively improves diastolic function in heart failure. Circulation, 1992, 86, I-375.
184. Rousseau, M.F.; Cocco, G.; Bouvy, T.; Cheron, P.; William, G.J.; Detry, J.M.R.; Pouleur, H. Effects of a novel metabolic modulator, ranolazine, on exercice tolerance and left ventricular filling dynamics in patientis with angina pectoris. Circulation, 1992, 86, I-714.
185. Hayashida, W.; van Eyll, C.; Rousseau, M.F.; Pouleur, H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc. Drugs Ther., 1994, 8, 741-747. (Pubitemid 24376754)
186. Moss, A.J.; Zareba, W.; Schwarz, K.Q.; Rosero, S.; McNitt, S.; Robinson, J.L. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J. Cardiovasc. Electrophysiol., 2008, 19, 1289-1293.
187. Laperche, T.; Logeart, D.; Cohen-Solal, A.; Gourgon, R. Potential interests of heart rate lowering drugs. Heart, 1999, 81, 336-341. (Pubitemid 29167119)
188. Kjekshus, J.; Gullestad, L. Heart rate as a therapeutic target in heart failure. Eur. Heart. J., 1999, 1(Suppl), H64-H69. (Pubitemid 29304286)
189. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode or action of selective blockers. Pharmacol. Res., 2006, 53, 399-406. (Pubitemid 43729047)
190. Mulder, P.; Barbier, S.; Chagraoui, A.; Richard, V.; Henry, J.P.; Lallemand, F.; Renet, S.; Lerebours, G.; Mahlberg-Gaudin, F.; Thuillez, C. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation, 2004, 109, 1674-1679. (Pubitemid 38451726)
191. Milliez, P.; Messaoudi, S.; Nehme, J.; Rodriguez, C.; Samuel, J.L.; Delcayre, C. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am. J. Physiol. Heart Circ. Physiol., 2009, 296, H435-H441.
192. Dedkov, E.; Zheng, W.; Christensen, L.; Weiss, R.; Mahlberg- Gaudin, F.; Tomanek, R.J. Preservation of coronary reserve by ivrabadine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am. J. Physiol., 2007, 293, H590-H598.
193. Manz, M.; Reuter, M.; Lauck, G.H.; Omran, H.; Jung, W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology, 2003, 100, 149-155. (Pubitemid 37465145)
194. De Ferrari, G.M.; Mazzuero, A.; Agnesina, L.; Bertoletti, A.; Lettino, M.; Campana, C.; Schwartz, P.J.; Tavazzi, L. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur. J. Heart Fail., 2008, 10, 550-555.
195. Fox, K.; Ford, I.; Steg, P.G.; Tendera, M.; Ferrari, R.; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, 2008, 372, 807-816.